Focused. se with 2008 F. lar Heart Diseas. date. ents With Valvul. Upd. gement of Patie. lines for Manag. HA 2006 Guidel ACC/AH. Fig.
|
|
- Alfred Todd
- 5 years ago
- Views:
Transcription
1 ACC/AH HA 2006 Guidel nic severe AI (Fig. 4). ned by age, ay also be helpful nd echo. For AI, ollow up may be or MRI rather than mension; SD, end lines for Manag gement of Patie Upd ents With Valvul date lar Heart Diseas se with 2008 F Focused Fi ig. 3 Fig. 4 Managemen Preop cath sh symptoms, a when there i Stable refe performed w echo to asses systolic dime t strategy for severe hould be performed nd coronary risk fact s discordance betwe ers to stable echo me with radionuclide vent ss LV volume and EF. ension. AS (Fig. 3) and chron routinely as determi tors. Cath & angio ma een clinical findings a asurements. Serial fo triculography (RVG) o DD, end diastolic dim 1
2 Fig. 5 Fig. 6 2
3 Fig. 7 Fig. 8 3
4 Aspirin is recommended in virtually all situations. Risk factors: a fib, LV dysfunction, previous thromboembolism, & hypercoagulable condition. INR should be maintained between 2.5 and 3.5 for aortic disc valves and Starr-Edwards valves Follow-Up Visits (Patients with prosthetic heart valves) 1. History, physical examination, and appropriate tests should be performed at the first postoperative outpatient evaluation, 2 to 4 weeks after hospital discharge. This should include a transthoracic Doppler echocardiogram if a baseline echocardiogram was not obtained before hospital discharge. (LOE: C) 2. Routine follow-up visits should be conducted annually, with earlier re-evaluations (with echocardiography) if there is a change in clinical status. (LOE: C) Patients with bioprosthetic valves may be considered for annual echocardiograms after the first 5 years in the absence of a change in clinical status. (LOE: C) CLASS III (avoid) Routine annual echocardiograms are not indicated in the absence of a change in clinical status in patients with mechanical heart valves or during the first 5 years after valve replacement with a bioprosthetic valve. (LOE: C) Bridging Therapy in Patients With Mechanical Valves Who Require Interruption of Warfarin Therapy for Noncardiac Surgery, Invasive Procedures, or Dental Care 1. In patients at low risk of thrombosis, (bileaflet mechanical AVR with no risk factors*) it is recommended that warfarin be stopped 48-72h before the procedure (so the INR falls to < 1.5) and restarted within 24h after the procedure. Heparin is usually unnecessary. (LOE: B) 2. In patients at high risk of thrombosis, (mechanical MV or mechanical AVR with any risk factor*), therapeutic IV UFH should be started when the INR is < 2.0 (typically 48h before surgery), stopped 4-6h before the procedure, restarted as early after surgery as bleeding stability allows, and continued until INR is therapeutic with warfarin therapy. (LOE: B) It is reasonable to give fresh frozen plasma to patients with mechanical valves who require interruption of warfarin therapy for emergency noncardiac surgery, invasive procedures, or dental care. FFP is preferable to high-dose vitamin K1. (LOE: B) In patients at high risk of thrombosis, therapeutic doses of subq UFH (15,000U Q12h) or LMWH (100U/kg Q12h) may be considered while INR is subtherapeutic. (LOE: B) CLASS III (avoid) In patients with mechanical valves who require interruption of warfarin therapy for noncardiac surgery, invasive procedures, or dental care, high-dose vitamin K1 should not be given routinely, because this may create a hypercoagulable condition. (LOE: B) *Risk factors: a fib, prior thromboembolism, LV dysfunction, hypercoagulable conditions, old-generation thrombogenic valves, mechanical tricuspid valves, or > 1 mechanical valve. *Concerns about the use of LMWH for mechanical valves persist, and package inserts continue to list a warning for this use of these medications. 4
5 Anticoagulation Regimen in Pregnant Patients With Mechanical Valves 1. Pts must receive continuous therapeutic anticoagulation & frequent monitoring. (LOE: B) 2. Pts who elect to stop warfarin between weeks 6 and 12 of gestation should receive continuous IV UFH, dose-adjusted UFH, or dose-adjusted SQ LMWH. (LOE: C) 3. Up to 36 wks of gestation, choice of continuous IV or dose-adjusted SQ UFH or LMWH, or warfarin should be discussed. With IV UFH, fetal risk is lower, but maternal risk of valve thrombosis, embolization, infection, osteoporosis, & HIT are higher. (LOE: C) 4. Pts who receive dose-adjusted LMWH, LMWH should be given twice daily SQ to maintain anti-xa level between 0.7 and 1.2 U per ml 4 h after administration. (LOE:C) 5. In pts who receive UFH, aptt should be at least 2x control. (LOE: C) 6. In pts who receive warfarin, INR should be 3.0 (2.5 to 3.5). (LOE: C) 7. Warfarin must be stopped; continuous IV UFH started 2-3 wks before delivery. (LOE: C) 1. Avoid warfarin wks 6 to 12 of gestation ti owing to the high h risk of fetal defects. (LOE: C) 2. Resume UFH 4-6 h after delivery & warfarin in the absence of sig. bleeding. (LOE: C) 3. Give low-dose aspirin (75 to 100 mg per day) in the second and third trimesters in addition to anticoagulation with warfarin or heparin. (LOE: C) CLASS III (avoid) 1. LMWH must not be given unless anti-xa is monitored 4-6 h afterwards. (LOE: C) 2. Dipyridamole should not be used instead of aspirin as an alternative antiplatelet agent because of its harmful effects on the fetus. (LOE: B) Embolic Events During Adequate Antithrombotic Therapy Patients who have definite embolic episodes while undergoing adequate antithrombotic therapy, the dosage of antithrombotic therapy should be increased, when safe, as follows: Warfarin, INR : warfarin dose increased to achieve INR of Warfarin, INR : warfarin dose may need to be increased to achieve INR of Not taking aspirin: aspirin mg per day should be initiated Warfarin plus aspirin mg per day: aspirin dose may also need to be increased to 325 mg per day if the higher dose of warfarin is not achieving the desired clinical result Aspirin alone: aspirin dose may need to be increased to 325 mg per day, clopidogrel 75 mg per day per day added, and/or warfarin added Excessive Anticoagulation In most patients excessive anticoagulation can be managed by withholding warfarin and monitoring the level of anticoagulation with serial INR determinations. INR > 5 greatly increases the risk of hemorrhage. However, rapid decreases in INR that lead to INR falling below therapeutic level increase the risk of thromboembolism. With INR of 5-10 (without bleeding), withhold warfarin and administer mg of oral vitamin K1 (phytonadione). The INR should be determined after 24 h and subsequently as needed. Warfarin therapy is restarted and adjusted dose appropriately to ensure that the INR is in the therapeutic range. In emergency situations, FFP is preferable to high-dose vitamin K1, especially parenteral vitamin K1, because use of the latter increases the risk of overcorrection to a hypercoagulable state. Low-dose IV vitamin K (1 mg) appears safe in this situation Thrombosis of Prosthetic Heart Valves With suspected prosthetic valve thrombosis: TTE & Doppler to assess hemodynamic severity, TEE and/or fluoroscopy to assess valve motion and clot burden. (LOE: B) 1. Emergency operation for thrombosed left-sided valve and either NYHA III IV symptoms or a large clot burden. (LOE: C) 2. Fibrinolysis for thrombosed right-sided valve, NYHA III IV symptoms or large clot burden. (LOE: C) 1. Fibrinolysis for thrombosed left-sided valve, NYHA I II symptoms & small clot burden; or NYHA III IV symptoms & small clot burden if surgery is high risk or not available. (LOE: B) 2. Fibrinolysis for obstructed, thrombosed left-sided valve, NYHA II IV symptoms and large clot burden if emergency surgery is high risk or not available. (LOE: C) 4. IV UFH instead of fibrinolysis for thrombosed valve, NYHA I II symptoms & small clot burden. (LOE: C) 5
6 8. INTRAOPERATIVE ASSESSMENT 1. Intraoperative TEE is recommended for valve repair surgery. (LOE: B) 2. Intraoperative TEE is recommended for valve replacement surgery with a stentless xenograft, homograft, or autograft valve. (LOE: B) 3. Intraoperative TEE is recommended for valve surgery for infective endocarditis. (LOE: B) Intraoperative TEE is reasonable for all patients undergoing cardiac valve surgery. (LOE: C) Table 31. Valvular Heart Lesions Associated With High Maternal and/or Fetal Risk During Pregnancy 1. Severe AS with or without symptoms 2. AR or MR with NYHA III-IV symptoms 3. MS with NYHA II-IV symptoms 5. Aortic and/or mitral disease with severe pulm. hypertension (PAP > 75% systemic) 6. Aortic and/or mitral disease with EF < Mechanical prosthesis requiring anticoagulation 8. Marfan syndrome with or without AR Major Criteria for Valve Selection Table 32. Valvular Heart Lesions Associated With Low Maternal and Fetal Risk During Pregnancy 1. Asymptomatic AS with mean gradient < 25 mmhg & AVA > 1.5 cm2) w/ LVEF > NYHA I or II AR or MR with normal LVEF 3. MVP with no MR or with mild to moderate MR with normal LVEF 4. Mild MS (MVA > 1.5 cm2, gradient < 5 mmhg) without severe pulmonary hypertension 5. Mild to mod pulmonary valve stenosis 1. A mechanical prosthesis is recommended for AVR in patients with a mechanical valve in the mitral or tricuspid position. (LOE: C) 2. A bioprosthesis is recommended for in patients of any age who will not take warfarin or who have major medical contraindications to warfarin therapy. (LOE: C) 1. Patient preference is a reasonable consideration in the selection of prosthesis (LOE: C): a. A mechanical prosthesis is reasonable in patients < 65 yrs who do not have a contraindication to anticoagulation, especially if they have embolic risk factors. b. A bioprosthesis is reasonable in pts < 65 yrs who elect to receive this valve for lifestyle considerations after detailed discussions of the risks of anticoagulation versus the likelihood that a second valve replacement may be necessary in the future. c. A bioprosthesis is reasonable in pts 65 yrs without risk factors for thromboembolism. 2. Aortic valve re-replacement with a homograft is reasonable for patients with active prosthetic valve endocarditis. (LOE: C) A bioprosthesis might be considered in a woman of childbearing age. (LOE: C) 3.3. Bicuspid Aortic Valve With Dilated Ascending Aorta 1. Pts with known bicuspid aortic valves should undergo an initial transthoracic echo (TTE) to assess the diameters of the aortic root and ascending aorta. (LOE: B) 2. Cardiac magnetic resonance imaging (CMR) or cardiac computed tomography (CCT) is indicated in pts with bicuspid aortic valves when morphology of the aortic root or ascending aorta cannot be assessed accurately by TTE. (LOE: C) 3. Pts with bicuspid aortic valves and dilatation of the aortic root or ascending aorta (diameter > 4.0 cm*) should undergo serial evaluation of aortic root/ascending aorta size and morphology by TTE, CMR or CCT on a yearly basis. (LOE: C) 4. Surgery to repair the aortic root or replace the ascending aorta is indicated in pts with bicuspid aortic valves if the diameter of the aortic root or ascending aorta is > 5.0 cm* or if the rate of increase in diameter is 0.5 cm per year. (LOE: C) 5. In pts with bicuspid valves undergoing AVR because of severe AS or AR, repair of the aortic root or replacement of the ascending aorta is indicated if the diameter of the aortic root or ascending aorta is greater than 4.5 cm*. (LOE: C). 1. It is reasonable to give beta-adrenergicadrenergic blocking agents to pts with bicuspid valves and dilated aortic roots (diameter > 4.0 cm*) who are not candidates for surgical correction and who do not have moderate to severe AR. (LOE: C) 2. CMR or CCT is reasonable in pts with bicuspid aortic valves when aortic root dilatation is detected by TTE to further quantify severity of dilatation and involvement of the ascending aorta. (LOE: B) *Consider lower threshold values for patients of small stature of either gender 6
Critical Care in Obstetrics: An Innovative and Integrated Model for Learning the Essentials
Critical Care in Obstetrics: An Innovative and Integrated Model for Learning the Essentials Pregnancy and Congenital Heart Disease Case Review Heidi M. Connolly, M.D. Professor of Medicine Chair for Education
More informationManagement of Patients With Valvular Heart Disease. ACC/AHA Pocket Guidelines
ACC/AHA Pocket Guidelines Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines July 2000 ACC/AHA
More informationValvular Heart Disease
Valvular Heart Disease B K Singh, MD, FACC Disclosures: None 1 CARDIAC CYCLE S2 S2=A2P2 S1=M1T1 S4 S1 S3 2 JVP Carotid S1 Slitting of S2 S3 S4 Ejection click Opening snap Dynamic Auscultation What is the
More informationSONOGRAPHER & NURSE LED VALVE CLINICS
SONOGRAPHER & NURSE LED VALVE CLINICS Frequency of visits and alerts AORTIC STENOSIS V max > 4.0 m/s or EOA < 1.0 cm 2 V max 3.5 4.0 m/s + Ca+ V max 3.0 4.0 m/s or EOA 1.0-1.5 cm 2 V max 2.5 3.0 m/s every
More informationSpotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France
Spotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France Faculty disclosure First name - last name I disclose the following
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationValve Disease in the Pregnant Patient
Valve Disease in the Pregnant Patient Julie B. Damp, MD December 6, 2012 VanderbiltHeart.com If single, do not allow marriage. If fertile, do not allow pregnancy. If pregnant, do not allow delivery. If
More informationA pregnant patient with a prosthetic valve Giacomo Boccuzzi, MD, FESC
A pregnant patient with a prosthetic valve Giacomo Boccuzzi, MD, FESC Department of Invasive Cardiology, Ospedale San Giovanni Bosco, Turin, Italy *C.V. was born the 24th May 1980 Rheumatic fever during
More informationLearn and LiveSM. ACC/AHA Pocket Guideline. Based on the ACC/AHA 2006 Guideline Revision. Management of Patients With. Valvular Heart Disease
Learn and LiveSM ACC/AHA Pocket Guideline Based on the ACC/AHA 2006 Guideline Revision Management of Patients With Valvular Heart Disease June 2006 Special thanks to Distributed through support from Medtronic
More informationProsthetic valve dysfunction: stenosis or regurgitation
Prosthetic valve dysfunction: stenosis or regurgitation Jean G. Dumesnil MD, FRCP(C), FACC, FASE(Hon) Quebec Heart and Lung Institute, Québec, Québec No disclosures Possible Causes of High Gradients in
More informationPREGNANCY AND CONGENITAL HEART DISEASE
PREGNANCY AND CONGENITAL HEART DISEASE SIDDHARTH JADHAV M.D. Assistant Professor of Radiology E.B. Singleton Department of Pediatric Radiology Texas Children's Hospital COMMERCIAL DISCLOSURE - None Objectives
More informationManagement of Valvular Heart Disease. Management of Valvular Heart Disease
Management of Valvular Heart Disease The Task Force on the Management of Valvular Heart Disease (Eur Heart J 2007;28:230-68) Chairperson Task Force Members Alec Vahanian, Paris (France) Task Force Members
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationProsthesis-Patient Mismatch or Prosthetic Valve Stenosis?
EuroValves 2015, Nice Prosthesis-Patient Mismatch or Prosthetic Valve Stenosis? Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE FESC Canada Research Chair in Valvular Heart Diseases Université LAVAL Disclosure
More informationESC/EACTS Guidelines for the Management of Valvular Heart Disease
ES/EATS Guidelines for the Management of Valvular Heart Disease European Journal of ardio-thoracic Surgery 2012 - Why do we need new guidelines on the management of valvular disease? New evidence has been
More informationAnticoagulation Therapy and Valve Surgery. Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon
Anticoagulation Therapy and Valve Surgery Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon Outline of lecture 1. Type of Valve Surgery 2. Anticoagulation requirements 3. Mechanical (Metallic) prosthetic
More informationThe Ross Procedure: Outcomes at 20 Years
The Ross Procedure: Outcomes at 20 Years Tirone David Carolyn David Anna Woo Cedric Manlhiot University of Toronto Conflict of Interest None The Ross Procedure 1990 to 2004 212 patients: 66% 34% Mean age:
More informationValvular heart disease (VHD) is present in 2.5% of the
2017 Focused Update for Management of Patients With Valvular Heart Disease: Summary of New Recommendations Richard Matiasz, MD; Vera H. Rigolin, MD Valvular heart disease (VHD) is present in 2.5% of the
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Co-Director, Echocardiography, Director, Interventional Cardiology Research, Beaumont Health System
More informationClinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!!
Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!! Abha'Khandelwal,'MD,'MS' 'Stanford'University'School'of'Medicine'
More informationPregnancy and Heart Disease Sharon L. Roble, MD Echo Hawaii 2016
1 Pregnancy and Heart Disease Sharon L. Roble, MD Echo Hawaii 2016 DISCLOSURES I have no disclosures relevant to today s talk 2 Cardiovascular Effects of Pregnancy Anatomic Ventricular muscle mass increases
More informationHeart Valves: Before and after surgery
Heart Valves: Before and after surgery Tim Sutton, Consultant Cardiologist Middlemore Hospital, Auckland Auckland Heart Group Indications for intervention in Valvular disease To prevent sudden death and
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More informationModern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies
Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies ERIC T. ROME D.O. HEART FAILURE, MECHANICAL ASSISTANCE AND TRANSPLANTATION CVI Left Ventricular Assist Device An
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More information2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD
2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD David L Saint M.D. Tallahassee Memorial Hospital Southern Medical Group Division of Cardiothoracic
More informationPregnancy and Heart Disease. Shilpa Kshatriya, MD, FACC Heartland Cardiology, PA
Pregnancy and Heart Disease Shilpa Kshatriya, MD, FACC Heartland Cardiology, PA Pregnancy and the Heart 2 % of pregnancies involve maternal CV disease CV disease does not preclude pregnancy but poses risk
More informationRF & RHD Workshop 22 nd March MANAGEMENT of RHEUMATIC HEART DISEASE in PREGNANCY. Dr Dorothy Radford
RF & RHD Workshop 22 nd March 2016 MANAGEMENT of RHEUMATIC HEART DISEASE in PREGNANCY Dr Dorothy Radford PREGNANCY PHYSIOLOGY Increased cardiac output 30%-50% Increased blood volume 30%-50% Increased heart
More information25 different brand names >44 different models Sizes mm
Types of Prosthetic Valves BIOLOGIC STENTED Porcine xenograft Pericardial xenograft STENTLESS Porcine xenograft Pericardial xenograft Homograft (allograft) Autograft PERCUTANEOUS MECHANICAL Bileaflet Single
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More information2019 Qualified Clinical Data Registry (QCDR) Performance Measures
2019 Qualified Clinical Data Registry (QCDR) Performance Measures Description: This document contains the 18 performance measures approved by CMS for inclusion in the 2019 Qualified Clinical Data Registry
More informationClinical Practice Committee Anticoagulation Bridging Document
Original: 10/23/06 Last Updated: 10/30/07 Clinical Practice Committee Do patients on long term oral anticoagulant therapy who require short term interruption of warfarin for an elective invasive procedure
More informationESC / EACTS new valvular guidelines- Update
ESC / EACTS new valvular guidelines- Update Yaron Shapira, MD The Dan Sheingarten echocardiography & valve clinic Rabin Medical Center, Beilinson Hospital, Petah-Tiqva Tel-Aviv University ESC valve guidelines
More informationAdult Cardiac Surgery
Adult Cardiac Surgery Mahmoud ABU-ABEELEH Associate Professor Department of Surgery Division of Cardiothoracic Surgery School of Medicine University Of Jordan Adult Cardiac Surgery: Ischemic Heart Disease
More informationECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction
Role of Stress Echo in Valvular Heart Disease ECHO HAWAII January 15 19, 2018 Kenya Kusunose, MD, PhD, FASE Tokushima University Hospital Japan Not only ischemia! Cardiomyopathy Prosthetic Valve Diastolic
More informationHow does taking warfarin affect Exercise Regimen? By Dr.*~LoOKTaO ~* ÿ
How does taking warfarin affect Exercise Regimen? By Dr.*~LoOKTaO ~* ÿ no consistent recommendations available regarding safety of certain sports & exercise any sports w/ high risk of trauma, especially
More informationCatherine Nelson-Piercy. Guy s & St Thomas Hospitals & Queen Charlotte s Hospital London, UK
Cardiac Disease and Pregnancy Catherine Nelson-Piercy Guy s & St Thomas Hospitals & Queen Charlotte s Hospital London, UK Physiological changes in pregnancy Cardiac Output (CO) increases by 40% Further
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Co Director, Echocardiography, Director, Interventional Cardiology Research, Beaumont Health System
More informationCASE IN... Anticoagulation: When to Start,When to Stop. The management of patients who require an. Meet Tracey. Anticoagulation
Anticoagulation: When to Start,When to Stop Ebtisam Bakhsh, MD; and James D. Douketis, MD, FRCPC Presented at McMaster University s Thrombosis and Hematology Update, October 2006. CASE IN... Anticoagulation
More informationValvular Heart Disease. Dr. HANAN ALBACKR
Valvular Heart Disease Dr. HANAN ALBACKR Valvular Heart Disease Format for this lecture IMPORTANT CLINICAL INFO know for boards, tests and clinical practice Spectrum of VHD Aortic Valve Mitral Valve Tricuspid
More informationSection 1: Initial Evaluation for Valvular Heart Disease Table 1: Initial Evaluation of an Asymptomatic Patient
Section 1: Initial Evaluation for Valvular Heart Disease Table 1: Initial Evaluation of an Asymptomatic Patient Indication 1. Unexplained murmur or abnormal heart sounds 2. Reasonable suspicion of valvular
More informationVALVULAR HEART DISEASE AND PULMONARY CIRCULATION
ESC CONGRESS HIGHLIGHTS VALVULAR HEART DISEASE AND PULMONARY CIRCULATION N. Ajmone Marsan (Leiden, NL) MD, PhD, FESC Conflicts of Interest None CONTENTS Pulmonary arterial hypertension Rheumatic heart
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationGestione peri-operatoria del paziente in terapia con antagonisti della vitamina K. B. Cosmi
Gestione peri-operatoria del paziente in terapia con antagonisti della vitamina K B. Cosmi Department of Angiology and Blood Coagulation S. Orsola-Malpighi University Hospital Bologna, Italy Overview Background
More informationPregnancy and Heart Disease. Alexandra A Frogoudaki Adult Congenital Heart Clinic ATTIKON University Hospital
Pregnancy and Heart Disease Alexandra A Frogoudaki Adult Congenital Heart Clinic ATTIKON University Hospital Pregnancy is not a state Hemodynamic changes During pregnancy Estrogens 1. Renin 2.
More informationExperience with 500 Stentless Aortic Valve Replacements
Experience with 500 Stentless Aortic Valve Replacements Dimitrios C. Iliopoulos, MD Cardiac Surgeon Ass. Professor of Surgery University of Athens, School of Medicine I declare no conflict of interest
More informationAortic Regurgitation & Aorta Evaluation
VALVULAR HEART DISEASE Regurgitation Valvular Lessions 2017 Aortic Regurgitation & Aorta Evaluation Jorge Eduardo Cossío-Aranda MD, FACC Chairman of Outpatient Care Department Instituto Nacional de Cardiología
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationPROSTHETIC VALVE BOARD REVIEW
PROSTHETIC VALVE BOARD REVIEW The correct answer D This two chamber view shows a porcine mitral prosthesis with the typical appearance of the struts although the leaflets are not well seen. The valve
More informationMaternal Cardiac Disease Diagnosis and Management
Maternal Cardiac Disease Diagnosis and Management Dr. Şevki ÇELEN ZTB Maternity and Teaching Hospital Department of Perinatology Heart diseases in pregnancy Today, 0.2-4% of all pregnancies are accompanied
More informationPregnancy, Heart Disease and Imaging. Hemodynamics. Decreased systemic vascular resistance. Physiology anemia
Pregnancy, Heart Disease and Imaging Sangeeta Shah, MD, FASE, FACC Associate Professor, Ochsner Clinical School of Medicine Advanced CV Imaging and Adult Congenital Heart Disease New Orleans, LA Hemodynamics
More information2.5 Other Hematology Consult:
The Warfarin Order Sheet has been approved by the P & T committee to be implemented by pharmacists. These orders are not used to treat patients with serious hemorrhagic complications. WARFARIN TARGET INR
More informationSeverity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root
The role of Cardiac Imaging modalities in evaluation & selection of patients for Trans-catheter Aortic Valve Implantation Dr.Saeed AL Ahmari Consultant Cardiologist Prince Sultan Cardaic Center, Riyadh
More informationChallenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest
Challenges in Anticoagulation Bridging and Emerging Therapies Ethan Cumbler MD FACP Associate Professor of Medicine Hospitalist Medicine Section University of Colorado Denver 2011 Disclosures and Relationships
More informationResults of Aortic Valve Preservation and Repair
Results of Aortic Valve Preservation and Repair Department of Cardiothoracic and Vascular Surgery Cliniques Universitaires St. Luc Brussels, Belgium Gebrine Elkhoury Institutional experience in AV preservation
More informationEffect of a combined anti-thrombotic therapy of thrombosis on prosthetic heart valves
Original Article Effect of a combined anti-thrombotic therapy of thrombosis on prosthetic heart valves Wei Wei, Taiming Dong, Zhichao Zheng, Shuping Huang Department of Cardiology, Guangdong Cardiovascular
More informationChallenges in Anticoagulation and Thromboembolism
Challenges in Anticoagulation and Thromboembolism Ethan Cumbler M.D. Assistant Professor of Medicine Hospitalist Medicine Section University of Colorado Denver May 2010 No Conflicts of Interest Objectives
More informationSlide 1: Perioperative Management of Anticoagulation
Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY
More informationEchocardiographic Evaluation of Mitral Valve Prostheses
Echocardiographic Evaluation of Mitral Valve Prostheses Dennis A. Tighe, M.D., FACC, FACP, FASE Cardiovascular Medicine University of Massachusetts Medical School Worcester, MA www.asecho.org 1 Nishimura
More informationWhich one of the following echocardiographic profiles most strongly indicates the need for aortic valve replacement? FS [
Question 46 A 45-year-old asymptomatic man returns for follow-up. He was diagnosed 10 years ago with aortic regurgitation due to a congentia lbicuspid aortic valve, He has never had endocarditis Which
More informationAortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
More informationWARFARIN: PERI OPERATIVE MANAGEMENT
WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationDisclosures. ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech
Disclosures ESC Munich 2012 Bernard Iung, MD Consultancy: Abbott Boehringer Ingelheim Bayer Servier Valtech Speaker s fee Edwards Lifesciences Sanofi-Aventis Decision Making in Patients with Multivalvular
More informationPregnancy and Cardiovascular Disease
Pregnancy and Cardiovascular Disease Cindy M. Martin, M.D. Co-Director, Adult Congenital and Cardiovascular Genetics Center No Disclosures Objectives Discuss the hemodynamic changes during pregnancy Define
More informationClinical Indications for Echocardiography
Clinical Indications for Echocardiography Echocardiography is widely utilised and potential applications are increasing with advances in technology. The aim of this document is two-fold: 1) To define clinical
More informationUnusual Causes of Aortic Regurgitation. Case 1
Unusual Causes of Aortic Regurgitation Judy Hung, MD Cardiology Division Massachusetts General Hospital Boston, MA No Disclosures Case 1 54 year old female with h/o cerebral aneurysm and vascular malformation
More informationMechanical heart valves and Anticoagulation. Dr. Alkesh ZALA Basic Physician trainee, Dept. of Cardiology, John Hunter hospital.
Mechanical heart valves and Anticoagulation Dr. Alkesh ZALA Basic Physician trainee, Dept. of Cardiology, John Hunter hospital. Today s discussion: Case review The currently Available and most commonly
More informationPROSTHETIC. V PROSTHETIC.V
PROSTHETIC. V PROSTHETIC.V VALVE TYPE The valve types now implanted include: 1-bileaflet and tilting disc mechanical valves, 2-stented porcine and pericardial xenografts, 3-stentless porcine xenografts,
More informationShould We Reconsider using Anticoagulation for Biological Tissue Valves
Should We Reconsider using Anticoagulation for Biological Tissue Valves No Disclosures Disclosures Watching grass grow Complete with audio 1 hour 8 minutes 9884 views Subclinical Leaflet Thrombosis in
More informationManagement of Difficult Aortic Root, Old and New solutions
Management of Difficult Aortic Root, Old and New solutions Hani K. Najm MD, Msc, FRCSC,, FACC, FESC Chairman, Pediatric and Congenital Heart Surgery Cleveland Clinic Conflict of Interest None Difficult
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Director, Interventional Cardiology Research, Beaumont Health System Associate Professor of Medicine,
More informationCases of Abnormal Prosthetic Valves
Cases of Abnormal Prosthetic Valves Sunil Mankad, MD, FACC, FCCP, FASE Associate Professor of Medicine Mayo Clinic College of Medicine Director, Transesophageal Echcoardiography Associate Director, Cardiology
More informationESC Guidelines on the Management of Cardiovascular Diseases during Pregnancy
ESC Guidelines on the Management of Cardiovascular Diseases during Pregnancy Task force on the management of CVD during pregnancy of the ESC Chair: Vera Regitz-Zagrosek, Charite, Berlin None DECLARATION
More informationCardiac disease in pre pr gnancy
IN THE NAME OF GOD Cardiac disease in pregn nancy MITRAL STENOSIS 33 y/o G3L2(2c/s) GA 34 + 5 CC: LP & dyspnea PMHx: MS sinse 4 yrs ago due to Rheumatism PSHx: 2c/s DHx: metoral 50 mg q6h/ ASA/ Enoxaparin
More informationMaternal Cardiac Disease In Pregnancy. August 25, 2017 PREGNANCY ECHO CONFERENCE
Maternal Cardiac Disease In Pregnancy August 25, 2017 PREGNANCY ECHO CONFERENCE Maternal Physiology Cardiac Output = HR x SV Non-pregnant: 4.5 L/min Pregnant: 6.0 L/min Increase most acute in first 10
More informationHoly Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH
Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH Goals and Objectives Discuss cardiac considerations for patients
More informationBridging anticoagulation definition
Bridging anticoagulation definition Giving a short-acting anticoagulant, consisting of sc LMWH or ev UFH for 10 to 12 day period during interruption of VKA therapy when the INR is not within therapeutic
More informationWorldwide rheumatic fever is the most common cause of valve disease. In industrialized areas, valvular disease of old age predominates
Michael Sumners DO Epidemiology Worldwide rheumatic fever is the most common cause of valve disease In industrialized areas, valvular disease of old age predominates Calcific aortic stenosis Functional
More informationTransthoracic Echocardiography in Adults
Medical Coverage Policy Effective Date...02/15/2018 Next Review Date...02/15/2019 Coverage Policy Number... 0510 Transthoracic Echocardiography in Adults Table of Contents Related Coverage Resources Coverage
More informationPeriprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy
Curriculum in Cardiology Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy Syed M. Jafri, MD, FACC Detroit, Mich Patients receiving chronic anticoagulation therapy
More informationOral anti-thrombotic therapy-management in patients requiring endoscopy
Oral anti-thrombotic therapy-management in patients requiring endoscopy Management of anti-thrombotic therapy in patients requiring endoscopy This guideline suggests appropriate management of patients
More informationMulti-imaging modality approach. Covadonga Fernández-Golfín Cardiac Imaging Unit. Cardiology Department. Ramón y Cajal Hospital.
Multi-imaging modality approach Covadonga Fernández-Golfín Cardiac Imaging Unit. Cardiology Department. Ramón y Cajal Hospital.Madrid Faculty Disclosure Covadonga Fernández-Golfín I have no financial relationships
More informationEVALUATION OF PREGNANT PATIENTS WITH HEART DISEASE. Karen Stout, MD University of Washington Seattle Children s Seattle, WA
EVALUATION OF PREGNANT PATIENTS WITH HEART DISEASE Karen Stout, MD University of Washington Seattle Children s Seattle, WA CASE PRESENTATION 24 year old woman with aortic regurgitation referred for evaluation
More informationECHOCARDIOGRAPHY. Patient Care. Goals and Objectives PF EF MF LF Aspirational
Patient Care Be able to: Perform and interpret basic TTE and X cardiac Doppler examinations Perform and interpret a comprehensive X TTE and cardiac Doppler examination Perform and interpret a comprehensive
More informationSESSION D5. The Heart of the Matter: Cardiac Disease in Pregnancy Brad M. Dolinsky, MD, MFM
37th Annual Advanced Practice in Primary and Acute Care Conference: October 9-11, 2014 2:45 SESSION D5 Session Description: The Heart of the Matter: Cardiac Disease in Pregnancy Brad M. Dolinsky, MD, MFM
More information2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17
2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical
More informationAortic stenosis and regurgitation
1 Aortic stenosis and regurgitation valvuloplasty and replacement Mitral regurgitation and stenosis valvuloplasty and repair/replacement 2 ASD PFO VSD PDA occlusion Left atrial appendage occlusion for
More informationTAVI and Valve Replacement Thromboprophylaxis. Warren Prokopiw Pharmacy Resident
TAVI and Valve Replacement Thromboprophylaxis Warren Prokopiw Pharmacy Resident 2011-2012 Case Mr MW 76 yo Admitted 14 May for worsening CHF PMH: Aortic Stenosis, CVD (CABG x4 1980, PCI x3 stent 2008)
More informationWARFARIN: PERI-OPERATIVE MANAGEMENT
WARFARIN: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin-treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationDr.ssa Loredana Iannetta. Centro Cardiologico Monzino
Dr.ssa Loredana Iannetta Centro Cardiologico Monzino Bicuspid aortic valve BAV is the most common congenital cardiac anomaly. Estimated incidence is 2% in general population. 4:1 male predominance. Frequency
More informationOutcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease
Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease TIRONE E. DAVID, MD ; SEMIN THORAC CARDIOVASC SURG 19:116-120c 2007 ELSEVIER INC. PRESENTED BY INTERN 許士盟 Mitral valve
More informationImaging Cardiovascular Disease in Pregnancy
Imaging Cardiovascular Disease in Pregnancy Karen Ordovas MD, MAS Associate Professor of Radiology and Medicine Director of Cardiac Imaging University of California San Francisco Cardiac MRI during pregnancy
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More informationCardiovascular disease complicates 1% to 3% of all
Pregnancy Complicated by Valvular Heart Disease: An Update Michael Nanna, MD; Kathleen Stergiopoulos, MD, PhD, FASE, FACC, FAHA Cardiovascular disease complicates 1% to 3% of all pregnancies and is responsible
More informationCase. 15-year-old boy with bicuspid AV Severe AR with moderate AS. Ross vs. AVR (or AVP)
Case 15-year-old boy with bicuspid AV Severe AR with moderate AS Ross vs. AVR (or AVP) AMC case 14-year-old boy with bicuspid AV Severe AS with mild AR Body size Bwt: 55 kg, Ht: 154 cm, BSA: 1.53 m 2 Echocardiography
More informationLong-Term Outcome of Patients With Aortic Regurgitation: Medical Management and Surgical Indications
24th Annual Advances in Heart Disease 16 December 2007 Long-Term Outcome of Patients With Aortic Regurgitation: Medical Management and Surgical Indications Melvin D. Cheitlin, M.D. Emeritus Professor of
More information